Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 513-522

  Clive, Sally ^a   Woo, Margaret M ^b   Nydam, Thomas ^b   Kelly, Lindsay ^c   Squier, Margaret ^b   Kagan, Mark ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Charles River   (United Kingdom)

Author keywords

DACi; Disposition; Excretion; Metabolism; Panobinostat

Indexed keywords

CARBON 14; DRUG METABOLITE; HISTONE DEACETYLASE; PANOBINOSTAT;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; FEMALE; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIOACTIVITY; RECTUM CANCER; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84867573822     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1940-9     Document Type: Article

References (13)

1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784
2. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233-241
3. Mateos MV, Spencer A, Taylor K, Lonial S, De La Rubia J, Facon T, Bengoudifa R, Klebsattel M, Hazell K, Bourquelot P, Rossi JF, Harousseau JL, Jagannath S, Wolf J, San Miguel J (2010) A phase IB study evaluating the combination of oral panobinostat (LBH589) with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Haematologica 95(Suppl 2):158, abstract 0390
4. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147:97-101
5. International Commission on Radiological Protection (ICRP) (1988) Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18(1-4)
6. Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413
7. Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601-612
8. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams- Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510
9. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K, Yamamoto N (2012) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 30:1096-1106
10. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S (2012, March 1) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma [Epub ahead of print]
11. Duvic M, Becker JC, Dalle S, Vanaclocha F, Bernengo MG, Lebbe C, Dummer R, Hirawat S, Zhang L, Marshood M, Laird G, Prince HM (2008) Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). Blood 112:1005
12. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68:805-813
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry: Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/ downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM292362. pdf. Accessed 12 June 2012